Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAF), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
bioAffinity Technologies, Inc. develops and commercializes noninvasive diagnostics for lung cancer and other lung diseases. The company’s first product, CyPath® Lung, is a sputum-based Laboratory Developed Test marketed by Precision Pathology Laboratory Services, a bioAffinity subsidiary, and uses flow cytometry with automated AI-informed analysis to identify cell populations associated with lung malignancy.
Recurring company news centers on CyPath® Lung commercialization, physician adoption, clinical case studies, pulmonary nodule management, lung cancer risk assessment, and post-treatment surveillance. Updates also cover financial results, laboratory-services focus, medical conference and physician-education activity, and research extending the company’s flow cytometry+AI platform toward asthma and COPD diagnostics.
bioAffinity Technologies (Nasdaq: BIAF) announced publication of a comprehensive clinical review and white paper by Chief Medical Officer Gordon H. Downie, MD, PhD, outlining a practical framework for integrating CyPath® Lung into pulmonary nodule evaluation and lung cancer surveillance across primary care, pulmonology and oncology.
The paper addresses the rising volume of pulmonary nodules driven by expanded screening, incidental findings and AI detection, and the need for improved risk stratification. It describes how CyPath Lung, a noninvasive sputum-based test that evaluates the lung microenvironment, has shown consistent clinical performance over three years of commercial use in helping physicians stratify malignancy risk, complement imaging and predictive models, and clarify challenging cases.
The framework proposes specialty-specific clinical pathways that incorporate CyPath Lung as an adjunct data point rather than a stand‑alone tool, emphasizing that direct analysis of sputum can reveal local immune responses, inflammation, genetic alterations and tumor biology not captured by blood-based diagnostics.
bioAffinity Technologies (Nasdaq: BIAF) announced a collaboration with targeted proteomic platform company Pictor to jointly develop and commercialize next-generation diagnostic tests for asthma and COPD. The partnership integrates bioAffinity’s flow cytometry of sputum immune cells with Pictor’s multi-analyte cytokine profiling to deliver high-throughput, lower-cost laboratory testing aimed at characterizing airway inflammation.
bioAffinity will own intellectual property arising from the new asthma/COPD tests, while Pictor retains and extends IP related to its targeted proteomic platform. The tests are expected to launch initially as CLIA-regulated Laboratory Developed Tests (LDTs). According to the company, asthma and COPD affect more than 40 million Americans and 650 million people worldwide, with the global therapeutics market valued at about $92 billion in 2024 and projected to exceed $108 billion in 2026 and $155 billion by 2030, underscoring the commercial potential for precision diagnostics that can guide targeted and biologic therapies.
bioAffinity Technologies (Nasdaq:BIAF) reported that Q2 2026 CyPath® Lung sales volume grew more than 200% year-over-year and over 30% versus Q1 2026. Physician offices ordering CyPath® Lung increased 155% from Q2 2025, and nearly 3,000 tests have been performed since launch. The company is advancing a large-scale longitudinal CyPath® Lung study and developing additional noninvasive diagnostics for asthma and COPD.
bioAffinity Technologies (Nasdaq:BIAF) reported preclinical in vitro data showing its proprietary siRNA gene-silencing approach selectively impairs proliferation of squamous and basal skin cancer cells while leaving non-cancerous skin cells unaffected. The work targets cell surface receptors CD320 and LRP2 and is covered by U.S. Patent No. 12,305,171.
According to the company, these results support further development of a potential topical, noninvasive treatment for common cutaneous cancers, subject to additional research and regulatory review. Findings will be presented at the 2026 RNA Therapeutics Symposium.
bioAffinity Technologies (Nasdaq:BIAF) closed a previously announced public offering for $3.2 million in aggregate gross proceeds, before fees and expenses.
The offering comprised 4,000,000 common shares at $0.80 per share, or pre-funded warrants at $0.793, each exercisable for one common share. WallachBeth Capital acted as sole placement agent.
bioAffinity Technologies (Nasdaq:BIAF) announced the closing of a previously announced public offering for aggregate gross proceeds of $3.2 million, before fees and expenses.
The offering comprised 4,000,000 shares of common stock (or pre-funded warrants) at $0.80 per share or $0.793 per pre-funded warrant, with WallachBeth Capital as sole placement agent.
bioAffinity Technologies (Nasdaq:BIAF) priced a registered public offering for expected gross proceeds of $3.2 million before fees and expenses.
The deal comprises 4,000,000 shares of common stock (or pre-funded warrants) at $0.80 per share, with closing anticipated around June 18, 2026. WallachBeth Capital is sole placement agent.
bioAffinity Technologies (Nasdaq: BIAF) priced a public offering for approximately $3.2 million in gross proceeds. The deal includes 4,000,000 common shares, or pre-funded warrants in lieu, at $0.80 per share or $0.793 per pre-funded warrant.
The offering is made under effective Form S-1 (File No. 333-296764) and is expected to close on or about June 18, 2026, subject to customary conditions. WallachBeth Capital serves as sole placement agent.
bioAffinity Technologies (Nasdaq:BIAF) announced a July 21, 2026 webinar focused on advancing veteran lung health. Clinical experts from Philips, bioAffinity Technologies and 4DMedical will discuss mobile CT screening, noninvasive CyPath® Lung testing, and functional lung imaging for earlier detection and improved management of respiratory disease in U.S. veterans.
bioAffinity Technologies (Nasdaq:BIAF) announced that the Society for Advanced Bronchoscopy will host a webinar on the noninvasive CyPath® Lung test and its role in managing early-stage lung cancer.
The June 16, 7 p.m. ET session will feature a multidisciplinary physician panel sharing real-world clinical use cases.